FDA Letter API

Sherman's 1400 Broadway, N.Y.C. LLC.

Letter data

Company
Sherman's 1400 Broadway, N.Y.C. LLC.
Recipient
Sherman's 1400 Broadway, N.Y.C. LLC. | United States
Issue date
2018-02-23
Posted date
Not available
FDA office
United States
Subject
Not available
Product
Not available
CMS ID
475207
Reference number
Not available
FEI
Not available
Inspection dates
Not available

Normalized citations

21 CFR: None found

21 U.S.C.: None found

Related FDA links

No related FDA letter link is present in the source index.

Full source text

CLOSEOUT LETTER Sherman's 1400 Broadway, N.Y.C. LLC. MARCS-CMS 475207 — February 23, 2018 More Warning Letters Warning Letters About Warning and Close-Out Letters Recipient: Sherman's 1400 Broadway, N.Y.C. LLC. United States Issuing Office: United States Center for Tobacco Products 10903 New Hampshire Avenue Silver Spring, MD 20993 FEB 23, 2018 VIA UPS William M. Sherman Executive Vice President Sherman's 1400 Broadway N.Y.C., Ltd. 10 Sterling Blvd. 3rd Floor Englewood, NJ 07631 RE: Warning Letter issued to Sherman's 1400 Broadway N.Y.C. LLC (Nat Sherman) (RW1500346) Dear Mr. Sherman: On August 27, 2015, the United States Food and Drug Administration's (FDA) Center for Tobacco Products (CTP) issued you a Warning Letter for the sale or distribution of modified risk tobacco products without an FDA order in effect that permits such sale or distribution, in violation of section 911 of the Federal Food, Drug, and Cosmetic Act (FD&C Act). Specifically, you sold or distributed Nat Sherman cigarette products described in product labeling as "Natural." In response to the Warning Letter, you stated that you implemented corrective actions to address the violations identified in the Warning Letter. You also submitted revised labeling and advertising for your products pursuant to section 905(i) of the Federal Food, Drug, and Cosmetic Act. FDA conducted an inspection of your manufacturing facility to confirm your corrective actions. After reviewing the results of this inspection, it appears that you have addressed the violations identified in the Warning Letter. This letter does not relieve you or your firm from the responsibility of taking all necessary steps to ensure sustained compliance with the FD&C Act and its implementing regulations or with other relevant legal authority. This letter also will not preclude any regulatory action should violations be observed in the future. Sincerely, /S/ Ele Ibarra-Pratt Director Division of Promotion, Advertising and Labeling Office of Compliance and Enforcement Center for Tobacco Products Content current as of: 02/28/2018